PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12150453-0 2002 Overexpression of cyclin D1 enhances taxol induced mitotic death in MCF7 cells. Paclitaxel 37-42 cyclin D1 Homo sapiens 18-27 12150453-2 2002 A moderate overexpression of ectopic cyclin D1 accelerated these G2/M associated events and resulted in a reduced clonogenic survival upon taxol treatment. Paclitaxel 139-144 cyclin D1 Homo sapiens 37-46 12150453-3 2002 Taxol treatment resulted in elevated expression of p53 and of p21, which was more pronounced and persistent in cyclin D1 overexpressing cells. Paclitaxel 0-5 cyclin D1 Homo sapiens 111-120 12150453-4 2002 Overexpression of cyclin D1 altered sensitivity to taxol by modulating exit from mitosis, which is controlled by p21. Paclitaxel 51-56 cyclin D1 Homo sapiens 18-27 12150453-5 2002 These results indicate that overexpression of cyclin D1 sensitizes MCF7 cells to treatment with taxol. Paclitaxel 96-101 cyclin D1 Homo sapiens 46-55 32431514-9 2020 Moreover, combination of TET and PTX obviously induced cell cycle arrest in SKOV3/PTX cells via increasing the level of p21 and decreasing the levels of c-Myc and Cyclin D1. Paclitaxel 33-36 cyclin D1 Homo sapiens 163-172 9710718-2 1998 We studied the effects of cytotoxic concentrations of Taxol (TXL) on cyclin D1 and B1 expression on human ovarian cancer cell lines. Paclitaxel 54-59 cyclin D1 Homo sapiens 69-78 9710718-2 1998 We studied the effects of cytotoxic concentrations of Taxol (TXL) on cyclin D1 and B1 expression on human ovarian cancer cell lines. Paclitaxel 61-64 cyclin D1 Homo sapiens 69-78 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Paclitaxel 102-107 cyclin D1 Homo sapiens 310-319 32660221-10 2020 Moreover, it can reduce the expression of CCND1 mRNA independent of the paclitaxel effect. Paclitaxel 72-82 cyclin D1 Homo sapiens 42-47 32431514-12 2020 Conclusion: We found that TET could enhance the sensitivity of SKOV3/PTX cells to PTX via inhibiting the beta-catenin/c-Myc/Cyclin D1 signaling pathway. Paclitaxel 69-72 cyclin D1 Homo sapiens 124-133 32431514-12 2020 Conclusion: We found that TET could enhance the sensitivity of SKOV3/PTX cells to PTX via inhibiting the beta-catenin/c-Myc/Cyclin D1 signaling pathway. Paclitaxel 82-85 cyclin D1 Homo sapiens 124-133 31206033-9 2019 Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway. Paclitaxel 126-129 cyclin D1 Homo sapiens 96-105 31467112-5 2019 Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro. Paclitaxel 348-351 cyclin D1 Homo sapiens 293-298 31467112-6 2019 Our results suggest the existence of a ZEB1/KLF5-mTOR-CCND1/ABCB1 axis in human cells that could be involved in PTX response pathways and functionally regulate inter-individualized breast cancer susceptibility and prognosis. Paclitaxel 112-115 cyclin D1 Homo sapiens 54-59 31467112-7 2019 Implications: The current study highlights the function of haplotypes of mTOR -78C/-141G and -78G/-141T, in affecting breast cancer susceptibility and PTX response regulated by ZEB1/KLF5-mTOR-CCND1/ABCB1 axis. Paclitaxel 151-154 cyclin D1 Homo sapiens 192-197 31206033-9 2019 Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway. Paclitaxel 268-271 cyclin D1 Homo sapiens 96-105 30244336-10 2019 Western blot and RT-PCR studies showed that only the LARP1 and CCND1 genes were over-expressed up to 2-5 times in all paclitaxel-resistant cell lines compared to the other investigated genes. Paclitaxel 118-128 cyclin D1 Homo sapiens 63-68 30326563-6 2018 PTX+BGJ398 induced cell cycle arrest and apoptosis in UC cells with mesenchymal characteristics was accompanied by downregulation of cyclin D1 protein and upregulation of gamma-histone 2A family member X and cleaved poly(ADP-ribose) polymerase. Paclitaxel 0-3 cyclin D1 Homo sapiens 133-142 27090655-9 2016 Analyzing mechanism of action interference of the mTOR inhibitor sirolimus shows specific impact on the drug resistance signature imposed by cisplatin and paclitaxel, further holding evidence for a synthetic lethal interaction to paclitaxel mechanism of action involving cyclin D1. Paclitaxel 230-240 cyclin D1 Homo sapiens 271-280 30101722-8 2018 After treatment with paclitaxel, cyclin D1 and CDK4 protein levels were similar to control values; meanwhile, cylinE1 and CDK2 protein amounts were reduced, with increased cyclin B1 levels, compared with control values (p<0.05). Paclitaxel 21-31 cyclin D1 Homo sapiens 33-42 25849888-6 2015 Interestingly, we found that c-myc and cyclin D1 increased significantly in transfected cells with increasing PTX concentration, and cell-survival rates remained at 60% while the PTX concentration increased. Paclitaxel 110-113 cyclin D1 Homo sapiens 39-48 27095936-0 2016 Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel. Paclitaxel 120-130 cyclin D1 Homo sapiens 17-22 27095936-3 2016 In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes. Paclitaxel 83-93 cyclin D1 Homo sapiens 158-163 27095936-11 2016 However, combined treatment of everolimus and paclitaxel significantly reduced BCL2 and CCND1 mRNA expression (p < 0.05). Paclitaxel 46-56 cyclin D1 Homo sapiens 88-93 27095936-13 2016 CONCLUSIONS: Down-regulation of CCND1 and BCL2 expression may be an important mechanism by which everolimus increases the therapeutic window of paclitaxel in cervical cancers. Paclitaxel 144-154 cyclin D1 Homo sapiens 32-37 25849888-6 2015 Interestingly, we found that c-myc and cyclin D1 increased significantly in transfected cells with increasing PTX concentration, and cell-survival rates remained at 60% while the PTX concentration increased. Paclitaxel 179-182 cyclin D1 Homo sapiens 39-48 26370682-9 2015 In addition, the present study raised the possibility that Clock and Bmal1 may in part play a role in preventing the cells from entering G1 to S phase of cell cycle via suppression of CyclinD1 expression, and thus acquiring resistance to Paclitaxel. Paclitaxel 238-248 cyclin D1 Homo sapiens 184-192 25633416-9 2015 FOXM1 effector genes such as CDK4, p53 and cyclin D1 were downregulated in gastric cancer cells by combination treatment with DIM and paclitaxel. Paclitaxel 134-144 cyclin D1 Homo sapiens 43-52 20883815-7 2011 Up-regulation of Cyclin-D1, Cox-2, XIAP and cIAP1 and phosphorylation of MAPKs, were completely inhibited on inactivation of NF-kappaB assigning a key regulatory role to NF-kappaB in the synergistic effect of paclitaxel and curcumin. Paclitaxel 209-219 cyclin D1 Homo sapiens 17-26 24024333-3 2013 Immunocytochemistry, Reverse transcription-polymerase chain reaction and western blotting were used to analyze the expression of MAPK1 (mitogen-activated protein kinases 1) and cyclin D1 in response to siRNA (small interfering RNA) transfection and taxol treatment. Paclitaxel 249-254 cyclin D1 Homo sapiens 177-186 23792647-10 2013 Combined CINK4 and paclitaxel produced synergistic anti-proliferative activity and increased apoptosis through reduced cyclin D1 and Bcl-2 in KRAS mutation-positive cancer cells. Paclitaxel 19-29 cyclin D1 Homo sapiens 119-128 22949827-0 2012 Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. Paclitaxel 57-62 cyclin D1 Homo sapiens 80-89 22949827-1 2012 The present study was designed to investigate the effects of cyclooxygenase (COX) inhibitors in combination with taxol on the expression of cyclin D1 and Ki-67 in human ovarian SKOV-3 carcinoma cells xenograft-bearing mice. Paclitaxel 113-118 cyclin D1 Homo sapiens 140-149 16243823-5 2005 Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1). Paclitaxel 29-39 cyclin D1 Homo sapiens 161-170